32 Gallbladder Cancer Clinical Trials Recruiting Now (May 2026): Biliary Tract, HER2 Zanidatamab T-DXd, Nanvuranlat, Durvalumab
Last updated: May 28, 2026
Current Clinical Trial Landscape
About gallbladder cancer:
Gallbladder cancer is a rare but aggressive biliary tract cancer. Often diagnosed at advanced stages due to vague symptoms. Treatment options are limited, making clinical trials particularly important.
Active research areas in 2026:
- Immunotherapy combinations (PD-1/PD-L1 + chemo ± CTLA-4; PD-1/TIGIT bispecific rilvegostomig)
- HER2-targeted therapy (~15-20% HER2+ gallbladder cancers): zanidatamab, T-DXd (DESTINY-BTC01), trastuzumab
- Neoadjuvant chemotherapy (NEOGB, PURITY) for locally advanced/high-risk disease
- Novel amino-acid transport inhibition: Nanvuranlat (LAT1, Beacon-BTC)
- Molecular-targeted maintenance after 1L chemo (SAFIR-ABC10)
- Hepatic arterial infusion chemotherapy (HAIC)
Standard of care: Resectable: surgery + adjuvant capecitabine. Unresectable/metastatic: gemcitabine + cisplatin ± durvalumab (TOPAZ-1).
Recruiting Trials by Treatment Setting
Neoadjuvant Therapy
Before surgery for locally advanced disease:
- NCT06712420 - Neoadjuvant chemotherapy vs upfront surgery (NEOGB, Phase 3)
- NCT06037980 - Cisplatin + gemcitabine + nab-paclitaxel (GAP triplet) vs upfront surgery in resectable high-risk biliary tract cancer (PURITY, Phase 2/3)
First-Line Metastatic/Unresectable
For previously untreated advanced disease:
- NCT07221253 - Rilvegostomig (PD-1/TIGIT bispecific) or durvalumab + chemotherapy (AB02, Phase 3)
- NCT07265674 - Nanvuranlat (LAT1 inhibitor) in advanced biliary tract cancer (Beacon-BTC, Phase 3)
- NCT07229625 - SHR-8068 (anti-CTLA-4) + adebrelimab (PD-L1) + platinum chemo vs durvalumab + chemo (Phase 3)
- NCT06529718 - Ivonescimab vs FOLFOX (SEVILLA / PRODIGE 110, Phase 2)
Molecular-Targeted Maintenance
Targeted maintenance after first-line chemotherapy, guided by tumor molecular profile:
- NCT05615818 - Molecular-targeted maintenance vs standard of care in advanced biliary cancer (SAFIR-ABC10 / PRODIGE 78, Phase 3)
Second-Line and Beyond
After progression on first-line therapy:
- NCT07146646 - Trifluridine/tipiracil + oxaliplatin (Phase 2)
- NCT07025174 - Sequential anti-angiogenic therapy after immunotherapy
Trials by Treatment Approach
Immunotherapy Combinations
Checkpoint inhibitors with chemotherapy or other agents:
- NCT06423170 - Camrelizumab combination (Phase 2)
- NCT05757336 - Gemcitabine + albumin-paclitaxel + sintilimab + bevacizumab
HER2-Targeted Therapy
For HER2-positive gallbladder cancer (~15-20%):
- NCT06282575 - Zanidatamab (HER2 bispecific) + standard of care in advanced HER2+ biliary tract cancer (Phase 3)
- NCT06467357 - Trastuzumab deruxtecan (T-DXd) ± rilvegostomig vs gemcitabine + cisplatin + durvalumab in treatment-naive HER2-expressing biliary tract cancer (DESTINY-Biliary Tract Cancer-01, Phase 3)
- NCT07062263 - Trastuzumab + chemo vs chemo alone in first-line HER2+ advanced biliary tract cancer (TAB-2, Phase 3)
- NCT05786716 - Trastuzumab + pertuzumab (DETERMINE Trial Arm 04)
KRAS-Targeted Therapy
- NCT07023731 - ARV-806 for KRAS G12D mutations (Phase 1/2)
Regional Therapies
Hepatic arterial infusion and radiation:
- NCT06852287 - GemOX hepatic arterial infusion + lenvatinib + PD-1 (Phase 2)
- NCT06214572 - Systemic therapy ± radiation therapy in unresectable nonmetastatic gallbladder cancer (RUGB, Phase 2/3)
Novel Targeted Agents
View all 32 gallbladder cancer trials on ClinicalTrials.gov →
Frequently Asked Questions
How do I find gallbladder cancer clinical trials?
Paste your medical summary into ClinTrialFinder to get AI-matched gallbladder and biliary tract cancer trials in minutes. The tool considers your HER2 expression, MSI status, FGFR alterations, and treatment history.
What gallbladder cancer trials are currently recruiting?
There are 32 recruiting interventional trials for gallbladder cancer including immunotherapy, HER2-targeted therapies, and novel agents for gallbladder and biliary tract cancers.
Find Gallbladder Cancer Trials Matched to Your Situation
Use ClinTrialFinder's AI-powered matching to find trials based on your specific biomarkers and treatment history.
Find Matching Trials